RU2009122198A - Производные 1,2,3-триазола в качестве ингибиторов сигма-рецепторов - Google Patents
Производные 1,2,3-триазола в качестве ингибиторов сигма-рецепторов Download PDFInfo
- Publication number
- RU2009122198A RU2009122198A RU2009122198/04A RU2009122198A RU2009122198A RU 2009122198 A RU2009122198 A RU 2009122198A RU 2009122198/04 A RU2009122198/04 A RU 2009122198/04A RU 2009122198 A RU2009122198 A RU 2009122198A RU 2009122198 A RU2009122198 A RU 2009122198A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- triazol
- propyl
- compound
- hydrogen
- Prior art date
Links
- 150000000177 1,2,3-triazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108010085082 sigma receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 150000002431 hydrogen Chemical group 0.000 claims abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 229910052736 halogen Chemical group 0.000 claims abstract 5
- 150000002367 halogens Chemical group 0.000 claims abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 5
- 229940002612 prodrug Drugs 0.000 claims abstract 5
- 239000000651 prodrug Substances 0.000 claims abstract 5
- 239000012453 solvate Substances 0.000 claims abstract 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract 4
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- IILGCCWJULTKPO-UHFFFAOYSA-N 1-[3-[4-(2,4-dichlorophenyl)-5-(4-methylphenyl)triazol-2-yl]propyl]piperidine Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=NN1CCCN1CCCCC1 IILGCCWJULTKPO-UHFFFAOYSA-N 0.000 claims abstract 2
- RXLFBOFHZJXGRZ-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCCCC1 RXLFBOFHZJXGRZ-UHFFFAOYSA-N 0.000 claims abstract 2
- SMIIMABNEHRULZ-UHFFFAOYSA-N 4-[3-[4-(2,4-dichlorophenyl)-5-(4-methylphenyl)triazol-2-yl]propyl]morpholine Chemical compound C1=CC(C)=CC=C1C(C(=N1)C=2C(=CC(Cl)=CC=2)Cl)=NN1CCCN1CCOCC1 SMIIMABNEHRULZ-UHFFFAOYSA-N 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 2
- 239000000460 chlorine Substances 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims abstract 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims abstract 2
- -1 [1,2,3] triazol-2-yl Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 208000004454 Hyperalgesia Diseases 0.000 claims 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000016192 Demyelinating disease Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 102000004895 Lipoproteins Human genes 0.000 claims 3
- 108090001030 Lipoproteins Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 206010053552 allodynia Diseases 0.000 claims 3
- 229940025084 amphetamine Drugs 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 230000006793 arrhythmia Effects 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960003920 cocaine Drugs 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 229960004756 ethanol Drugs 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 201000003723 learning disability Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 229960002715 nicotine Drugs 0.000 claims 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 238000005804 alkylation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- QPHKZDGGFGGCDJ-UHFFFAOYSA-N 1-[2-(4-phenyltriazol-2-yl)ethyl]azepane Chemical compound C1CCCCCN1CCN(N=1)N=CC=1C1=CC=CC=C1 QPHKZDGGFGGCDJ-UHFFFAOYSA-N 0.000 claims 1
- QODYALOVHNCCKF-UHFFFAOYSA-N 1-[2-(4-phenyltriazol-2-yl)ethyl]piperidine Chemical compound C1CCCCN1CCN(N=1)N=CC=1C1=CC=CC=C1 QODYALOVHNCCKF-UHFFFAOYSA-N 0.000 claims 1
- GNNUFCDGSDJQPE-UHFFFAOYSA-N 1-[2-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCN1CCCCC1 GNNUFCDGSDJQPE-UHFFFAOYSA-N 0.000 claims 1
- FXECWAXRHRBMMG-UHFFFAOYSA-N 1-[3-(4-methyl-5-phenyltriazol-2-yl)propyl]piperidine Chemical compound N1=C(C=2C=CC=CC=2)C(C)=NN1CCCN1CCCCC1 FXECWAXRHRBMMG-UHFFFAOYSA-N 0.000 claims 1
- ZAOFUUGYVOBXKH-UHFFFAOYSA-N 1-[3-(4-phenyltriazol-2-yl)propyl]azepane Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCCCCC1 ZAOFUUGYVOBXKH-UHFFFAOYSA-N 0.000 claims 1
- ZJCIOJGJGJKZBR-UHFFFAOYSA-N 1-[3-(4-phenyltriazol-2-yl)propyl]piperidine Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCCCC1 ZJCIOJGJGJKZBR-UHFFFAOYSA-N 0.000 claims 1
- RXMSTAIWAPIJNB-UHFFFAOYSA-N 1-[3-[4-(4-bromo-2-fluorophenyl)triazol-2-yl]propyl]piperidine Chemical compound FC1=CC(Br)=CC=C1C1=NN(CCCN2CCCCC2)N=C1 RXMSTAIWAPIJNB-UHFFFAOYSA-N 0.000 claims 1
- VWKBXKVJNNHWBY-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]-4-phenylpiperazine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCN(C=2C=CC=CC=2)CC1 VWKBXKVJNNHWBY-UHFFFAOYSA-N 0.000 claims 1
- GNBYZIZVAFKIAD-UHFFFAOYSA-N 1-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]-4-phenylpiperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCC(C=2C=CC=CC=2)CC1 GNBYZIZVAFKIAD-UHFFFAOYSA-N 0.000 claims 1
- RANJVMWCDJUSPP-UHFFFAOYSA-N 1-[4-(4-phenyltriazol-2-yl)butyl]azepane Chemical compound C1CCCCCN1CCCCN(N=1)N=CC=1C1=CC=CC=C1 RANJVMWCDJUSPP-UHFFFAOYSA-N 0.000 claims 1
- OWXBJIZYYYWPOK-UHFFFAOYSA-N 1-[4-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]butyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCCN1CCCCC1 OWXBJIZYYYWPOK-UHFFFAOYSA-N 0.000 claims 1
- SLLZNMBEIVMVOK-UHFFFAOYSA-N 1-[5-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]pentyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCCCN1CCCCC1 SLLZNMBEIVMVOK-UHFFFAOYSA-N 0.000 claims 1
- KNFJJWWYDSKJKZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-phenyl-2-(3-pyrrolidin-1-ylpropyl)triazole Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCCC1 KNFJJWWYDSKJKZ-UHFFFAOYSA-N 0.000 claims 1
- PDHJSTSIOUMGPN-UHFFFAOYSA-N 4-[2-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]ethyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCN1CCOCC1 PDHJSTSIOUMGPN-UHFFFAOYSA-N 0.000 claims 1
- MLVGRNXYOQCXIV-UHFFFAOYSA-N 4-[3-(4-phenyltriazol-2-yl)propyl]morpholine Chemical compound N1=CC(C=2C=CC=CC=2)=NN1CCCN1CCOCC1 MLVGRNXYOQCXIV-UHFFFAOYSA-N 0.000 claims 1
- CKRUXDNBPZPWFQ-UHFFFAOYSA-N 4-[3-[4-(4-chlorophenyl)-5-phenyltriazol-2-yl]propyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C(=N1)C=2C=CC=CC=2)=NN1CCCN1CCOCC1 CKRUXDNBPZPWFQ-UHFFFAOYSA-N 0.000 claims 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 238000006352 cycloaddition reaction Methods 0.000 claims 1
- CGTZBPXNCBEGCF-UHFFFAOYSA-N cyclohexyl-[3-(4-phenyltriazol-2-yl)propyl]azanium;oxalate Chemical compound [O-]C(=O)C([O-])=O.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH2+]C1CCCCC1.N1=CC(C=2C=CC=CC=2)=NN1CCC[NH2+]C1CCCCC1 CGTZBPXNCBEGCF-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380289A EP1921071A1 (en) | 2006-11-10 | 2006-11-10 | 1,2,3- triazole derivatives as sigma receptor inhibitors |
| EP06380289.6 | 2006-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009122198A true RU2009122198A (ru) | 2010-12-20 |
Family
ID=37963991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009122198/04A RU2009122198A (ru) | 2006-11-10 | 2007-11-07 | Производные 1,2,3-триазола в качестве ингибиторов сигма-рецепторов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8193223B2 (enExample) |
| EP (2) | EP1921071A1 (enExample) |
| JP (1) | JP2010509281A (enExample) |
| KR (1) | KR20090087032A (enExample) |
| CN (1) | CN101589029A (enExample) |
| AU (1) | AU2007316606A1 (enExample) |
| BR (1) | BRPI0718586A2 (enExample) |
| CA (1) | CA2668996A1 (enExample) |
| ES (1) | ES2413559T3 (enExample) |
| MX (1) | MX2009004745A (enExample) |
| RU (1) | RU2009122198A (enExample) |
| WO (1) | WO2008055933A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666728C2 (ru) * | 2013-04-19 | 2018-09-12 | Лабораториос Дель Др. Эстеве, С.А. | Трициклические триазольные соединения |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2395003A1 (en) | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2548878A1 (en) * | 2011-07-21 | 2013-01-23 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2752411A1 (en) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| EP2989105B1 (en) | 2013-04-23 | 2020-03-11 | Esteve Pharmaceuticals, S.A. | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments |
| MA38569A1 (fr) | 2013-04-23 | 2017-03-31 | Esteve Labor Dr | Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments |
| EP2832720A1 (en) | 2013-07-30 | 2015-02-04 | Laboratorios Del. Dr. Esteve, S.A. | 1,2-disubstituted cyclobutyl compounds |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
| HUE058156T2 (hu) | 2015-01-30 | 2022-07-28 | Neurocrine Biosciences Inc | Helyettesített triazolok és ezekkel kapcsolatos eljárások |
| CN106866555B (zh) * | 2017-02-08 | 2019-04-30 | 东南大学 | 1-二苯甲基-4-甲基哌嗪类化合物其制备方法和应用 |
| WO2020123847A1 (en) * | 2018-12-12 | 2020-06-18 | Rutgers, The State University Of New Jersey | Organic compounds |
| CN116178286B (zh) * | 2021-11-26 | 2024-12-03 | 华东师范大学 | 一种n2烷基取代的三氮唑衍生物及其合成方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| AU2002224478A1 (en) * | 2000-11-02 | 2002-05-15 | K And K Biosciences, Inc. | Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke |
| EP1954128A4 (en) * | 2005-11-04 | 2010-09-22 | Merck Sharp & Dohme | DIPHENYLMETHANE DERIVATIVES AS AN INHIBITORS OF THE LEUKOTRIEN BIOSYNTHESIS |
-
2006
- 2006-11-10 EP EP06380289A patent/EP1921071A1/en not_active Withdrawn
-
2007
- 2007-11-07 ES ES07822321T patent/ES2413559T3/es active Active
- 2007-11-07 WO PCT/EP2007/062010 patent/WO2008055933A1/en not_active Ceased
- 2007-11-07 CN CNA2007800418260A patent/CN101589029A/zh active Pending
- 2007-11-07 US US12/514,213 patent/US8193223B2/en not_active Expired - Fee Related
- 2007-11-07 AU AU2007316606A patent/AU2007316606A1/en not_active Abandoned
- 2007-11-07 BR BRPI0718586-3A2A patent/BRPI0718586A2/pt not_active Application Discontinuation
- 2007-11-07 CA CA002668996A patent/CA2668996A1/en not_active Abandoned
- 2007-11-07 EP EP07822321A patent/EP2097392B1/en not_active Not-in-force
- 2007-11-07 KR KR1020097011468A patent/KR20090087032A/ko not_active Withdrawn
- 2007-11-07 RU RU2009122198/04A patent/RU2009122198A/ru not_active Application Discontinuation
- 2007-11-07 JP JP2009535724A patent/JP2010509281A/ja active Pending
- 2007-11-07 MX MX2009004745A patent/MX2009004745A/es not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666728C2 (ru) * | 2013-04-19 | 2018-09-12 | Лабораториос Дель Др. Эстеве, С.А. | Трициклические триазольные соединения |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2097392A1 (en) | 2009-09-09 |
| EP1921071A1 (en) | 2008-05-14 |
| MX2009004745A (es) | 2009-05-22 |
| CN101589029A (zh) | 2009-11-25 |
| EP2097392B1 (en) | 2013-03-13 |
| WO2008055933A1 (en) | 2008-05-15 |
| US20100004265A1 (en) | 2010-01-07 |
| JP2010509281A (ja) | 2010-03-25 |
| AU2007316606A1 (en) | 2008-05-15 |
| ES2413559T3 (es) | 2013-07-16 |
| US8193223B2 (en) | 2012-06-05 |
| KR20090087032A (ko) | 2009-08-14 |
| CA2668996A1 (en) | 2008-05-15 |
| BRPI0718586A2 (pt) | 2014-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009122198A (ru) | Производные 1,2,3-триазола в качестве ингибиторов сигма-рецепторов | |
| RU2009122197A (ru) | Производные 1,2,4-триазолы в качестве ингибиторов сигма-рецептора | |
| JP2010509281A5 (enExample) | ||
| RU2411238C2 (ru) | Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств | |
| JP2010509280A5 (enExample) | ||
| AU2005210163B2 (en) | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| RU2168507C2 (ru) | Тетрагидропиридин- или 4-гидроксипиперидин-алкилазолы или их физиологически приемлемые соли, способы их получения и фармацевтическая композиция на их основе | |
| RU2008126383A (ru) | ПРОИЗВОДНЫЕ 2,4,5-ТРИФЕНИЛИМИДАЗОЛИНА КАК ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ БЕЛКАМИ p53 И MDM2, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ СРЕДСТВ | |
| CA3009971C (en) | Cyclic amine derivative and medical use thereof | |
| KR20070073887A (ko) | 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정 | |
| JP2008520637A5 (enExample) | ||
| JP2009528318A5 (enExample) | ||
| CA2725563C (en) | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof | |
| PL209135B1 (pl) | Pochodna aryloamidyny lub jej sól oraz środek grzybobójczy | |
| JP2009528319A5 (enExample) | ||
| RU2007111118A (ru) | Ингибиторы сигма-рецептора | |
| US8772299B2 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | |
| US10881649B2 (en) | Therapeutic agent or preventive agent for alopecia areata | |
| SK286274B6 (sk) | Substituované Mannichove bázy pyrolov na použitiena potláčanie bolesti a alergických reakcií, spôsob ich prípravy, liek a použitie | |
| BG60318B2 (bg) | Метод за получаване на триазолил тиоамидни производни |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110311 |